Skip to main content
Clinton F. Stewart, PharmD
Clinton F. Stewart, PharmD

Education

BSPh – Auburn University
PharmD – University of Tennessee, Memphis, TN

Honors & Awards

  • 2012 Research Advisor Award, University of Tennessee Health Science Center, College of Graduate Health Sciences
  • 2009 Fellow, American Association of Pharmaceutical Scientists
  • 1994 Fellow, American College of Clinical Pharmacists

Research Interests

  • CNS and tumor penetration of novel agents used to treat pediatric CNS tumors in relevant mouse models
  • Pharmacokinetic and pharmacodynamic modeling and simulation to derive safe and effective anti-cancer drug regimens for infants and young children with brain tumors
  • Novel methods to optimize drug exposure in children with cancer (eg, pharmacokinetically guided dosing)

Improving Drug Therapy for Children with Brain Tumors

Selected Publications

See full list of publications

Bagchi A, Orr BA, Campagne O, Dhanda S, Nair S, Tran Q, Christensen AM, Gajjar A, Furtado LV, Vasilyeva, Boop F, Stewart C, Robinson GW. Lorlatinib in a child with ALK-fusion-positive high-grade glioma. N Eng J Med 358:761-763; 2021. (PMC in progress)

Panetta JC, Campagne O, Gartrell J, Furman W, Stewart CF. Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study. Clin Translation Sci Jun 1 2021, doi: 10.1111/cts. 13069.

Campagne O, Yeo KK, Fangusaro J, Stewart CF. Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. Clin Pharmacokinet 60:283-303; 2021. (PMCID: PMC7935771)

Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Campagne O, Banerjee A, Gururangan S, Kilburn L, Goldman S, Qaddoumi I, Baxter P, Vezina G, Bregman C, Patay Z, Jones JY, Stewart CF, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M. A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study. Neuro Oncol noab047; 2021 [Epub ahead of print]. (PMC in progress)

DeWire MD, Fuller C, Campagne O, Lin T, Pan H, Young Poussaint T, Baxter PA, Hwang EI, Bukowinski A, Dorris K, Hoffman L, Waanders AJ, Karajannis MA, Stewart CF, Onar-Thomas A, Fouladi M, Dunkel IJ. A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clin Cancer Res 27:2442-2451; 2021.[Epub ahead of print]. (PMC in progress)

Endersby R, Whitehouse J, Pribnow A, Kuchibhotla M, Hii H, Carline B, Gande S, Stripay J, Ancliffe M, Howlett M, Schoep T, George C, Andradas C, Dyer P, Schluck M, Patterson B, Tacheva-Gigorova SK, Cooper MN, Robinson G, Stewart C, Pfister SM, Kool M, Milde T, Gajjar A, Johns T, Wechsler-Reya RJ, Roussel MF, Gottardo NG. Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Sci Transl Med 13:eaba7401; 2021. (PMC in progress)

Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, Mahajan A, Su J, Bouffet E, Bartels U, Schechter T, Hassall T, Robertson T, Nicholls W, Gururangan S, Schroeder K, Sullivan M, Wheeler G, Hansford JR, Kellie SJ, McCowage G, Cohn R, Fisher MJ, Krasin MJ, Stewart CF, Broniscer A, Buchhalter I, Tatevossian RG, Orr BA, Neale G, Klimo P Jr, Boop F, Srinivasan A, Pfister SM, Gilbertson RJ, Onar-Thomas A, Ellison DW, Northcott PA. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol 39:822-835; 2021. (PMC in progress)

Husband HR, Campagne O, He C, Zhu X, Bianski BM, Baker SJ, Shelat AA, Tinkle CL, Stewart CF. Model-based evaluation of image-guided fractionated whole-brain radiation therapy in pediatric diffuse intrinsic pontine glioma xenografts. CPT Pharmacometrics Syst Pharmacol doi: 10.1002/psp4.12627; 2021. [Online ahead of print]. (PMC in progress)

Campagne O, Davis A, Maharaj AR, Zhong B, Stripay J, Farmer D, Roussel MF, Stewart CF. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model. Eur J Pharm Sci 142:105106; 2020. (PMCID: PMC6925336).

Panetta JC, Roberts JK, Huang J, Lin T, Daryani VM, Harstead KE, Patel YT, Onar-Thomas A, Campagne O, Ward DA, Broniscer A, Robinson G, Gajjar A, Stewart CF. Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumors. Br J Clin Pharmacol 86:362-371; 2020. (PMCID: PMC7015755).

Campagne O, Zhong B, Nair S, Lin T, Huang J, Onar-Thomas A, Robinson G, Gajjar A, Stewart CF. Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. Clin Cancer Res 26:1563-1573; 2020. (PMCID: PMC7124978).

Federico SM, Caldwell KJ, McCarville MB, Daryani VM, Stewart CF, Mao S, Wu J, Davidoff AM, Santana VM, Furman WL, Pappo AS, Navid F. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors. European J Cancer 132:35-42; 2020. (PMCID: PMC7958650)

Fletcher EP, Burckart GJ, Robinson GW, Reaman FH, Stewart CF. The RACE to develop new targeted therapies for children with CNS tumors. Clin Pharmacol Ther 108:434-436; 2020. doi: 10.1002/cpt.1937. Online ahead of print. (PMC: in progress)

Zong B, Campagne O, Salloum R, Purzner T, Stewart CF. LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors. J Chromatogr B Analyt Technol Biomed Life Sci 1152:122254-122263; 2020. (PMCID: PMC7484447)

Federico SM, Pappo AS, Sahr N, Sykes A, Campagne O, Stewart CF, Clay MR, Bahrami A, McCarville MB, Kaste SC, Santana VM, Helmig S, Gartrell J, Shelat A, Brennan RC, Hawkins D, Godwin K, Bishop MW, Furman WL, Stewart E. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer 137:204-213; 2020. (PMC in progress)

Santana VM, Sahr N. Tatevossian RG, Jia S, Campagne O, Sykes A, Stewart CF, Furman WL, McGregor LM. A phase I trial of everolimus and bevacizumab in children with recurrent solid tumors. Cancer 126:1749-1757; 2020. (PMCID: PMC7103504)

Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AJ, Lindeman N, Banerjee A, Packer RJ, Kilburn L, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel I, Fouladi M. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type1-associated recurrent, refractory, or progressive low-grade glioma: a multicenter, phase 2 trial. Lancet Oncology 20:1011-1022; 2019. (PMCID: PMC6628202).

Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicenter phase 2 trial. Lancet Oncology 19:768-784; 2018. (PMC: PMC6078206) PMID: 29778738.

Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. A phase I trial of the MEK inhibitor selumetinib AZD6244 in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium PBTC study. Neuro-Oncol 19: 1135-1144, 2017. PMCID: PMC5570236 PMID: 28339824

Brennan RC, Qaddoumi I, Mao S, Wu J, Billups CA, Stewart CF, Hoehn ME, Rodriguez-Galindo C, Wilson MW. Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35:72-77, 2017. PMCID: PMC5455691 PMID: 28034080

Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF. Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nephrol 2017. PMCID: PMC5712286 PMID: 28573537

Patel YT, Daryani VM, Patel P, Zhou D, Fangusaro J, Carlile DJ, Martin PD, Aarons L, Stewart CF. Population pharmacokinetics of selumetinib and its metabolite n-desmethyl-selumetinib in adult patients with advanced solid tumors and children with low-grade gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314, 2017. PMCID: PMC5445231 PMID: 28326681

Stewart CF, Robinson GW. Development of molecularly targeted therapies to treat pediatric malignancies. Clin Pharmacol Ther 102:752-753, 2017. PMCID: PMC5656826 PMID: 28836264

Daryani VM, Patel YT, Tagen M, Turner DC, Carcaboso AM, Atkinson JM, Gajjar A, Gilbertson RJ, Wright KD, Stewart CF. Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children with Pediatric Ependymoma. CPT Pharmacometrics Syst Pharmacol 5:211-221, 2016. PMCID: PMC4834132 PMID: 27104090

Patel YT, Jacus MO, Davis AD, Boulos N, Turner DC, Vuppala PK, Freeman BB 3rd, Gilbertson RJ, Stewart CF. Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study. Drug Metab Dispos 44:591-4, 2016. PMCID: PMC4810761 PMID: 26802130

Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, Roussel MF, Finkelstein D, Goumnerova L, Perreault S, Wadhwa E, Cho YJ, Stewart CF, Gilbertson RJ. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell 29:508-22, 2016. PMCID: PMC4829447 PMID: 27050100

Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metab Dispos 7:1116-22, 2016. PMCID: PMC4931885 PMID: 27052877

Jacus MO, Rahija R, Davis A, Throm SL, Stewart CF. An observational evaluation of mice during cerebral microdialysis procedures used in pediatric brain tumor research. J Am Assoc Lab Anim Sci 54:304-10, 2015. PMCID: PMC4460944 PMID: 26045457

Morfouace M, Cheepala SB, Jackson S, Fukuda Y, Patel YT, Soghra F, Kawauchi D, Shelat AA, Stewart CF, Sorrentino B, Schuetz JD, Roussel MF. ABCG2 transporter expression impacts Group3 Medulloblastoma response to chemotherapy. Cancer Res 75:3879-3889, 2015. PMCID: PMC4573843 PMID: 26199091

Patel Y, Jacus M, Boulos N, Dapper J, David A, Vuppala P, Freeman III B, Mohankumar K, Throm S, Gilbertson R, Stewart CF. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. Cancer Chemotherap Pharmacol 75:897-906, 2015. PMID: PMC4420645 PMID: 25724157

Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol 17:1620-7, 2015. PMCID: PMC4633933 PMID: 26541630

Xu H, Robinson GW, Huang Jie, Lim JY-S, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JY. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics 47:263-266, 2015. PMCID: PMC4358157 PMID: 25665007

Show More

Jacus MO, Throm SL, Turner DC, Patel YT, Freeman BB 3rd, Morfouace M, Boulos N, Stewart CF. Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data. Eur J Pharm Sci 57:41-7, 2014. PMCID: PMC4004667 PMID: 24269626

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Robinson S, Turner D, Zindy F, Wang Y-D, Finkelstein D, Bihannic L, Puget S, Ayrault O, Li X-N, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF. Pemetrexed and gemcitabine as combination therapy for the treatment of group 3 medulloblastoma. Cancer Cell 25:516-29, 2014. PMCID: PMC3994669 PMID: 24684846

Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res 19:6305-12, 2013. PMCID: PMC3856244 PMID: 24077351

Yang JJ, Lim JY-S, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead EH, Shuyu E, Robinson GW, Evans WE, Pappo A, Zuo J, Relling MV, Onar-Thomas A, Gajjar A, Stewart CF. The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-induced Ototoxicity in Children with Cancer. Clinical Pharmacol Therap 94:252-9, 2013. PMCID: PMC3883563 PMID: 23820299

Last update: September 2021